These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 31173466)

  • 81. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations.
    Zenker M; Lehmann K; Schulz AL; Barth H; Hansmann D; Koenig R; Korinthenberg R; Kreiss-Nachtsheim M; Meinecke P; Morlot S; Mundlos S; Quante AS; Raskin S; Schnabel D; Wehner LE; Kratz CP; Horn D; Kutsche K
    J Med Genet; 2007 Feb; 44(2):131-5. PubMed ID: 17056636
    [TBL] [Abstract][Full Text] [Related]  

  • 82. SHOC2-MRAS-PP1 complex positively regulates RAF activity and contributes to Noonan syndrome pathogenesis.
    Young LC; Hartig N; Boned Del Río I; Sari S; Ringham-Terry B; Wainwright JR; Jones GG; McCormick F; Rodriguez-Viciana P
    Proc Natl Acad Sci U S A; 2018 Nov; 115(45):E10576-E10585. PubMed ID: 30348783
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Assessing the gene-disease association of 19 genes with the RASopathies using the ClinGen gene curation framework.
    Grant AR; Cushman BJ; Cavé H; Dillon MW; Gelb BD; Gripp KW; Lee JA; Mason-Suares H; Rauen KA; Tartaglia M; Vincent LM; Zenker M
    Hum Mutat; 2018 Nov; 39(11):1485-1493. PubMed ID: 30311384
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [A case report of Noonan syndrome diagnosed in primary healthcare].
    Villaroel-Vargas J; Molina-Vargas L; Zurita-Leal A; Zavala-Calahorrano A
    Medwave; 2020 Feb; 20(2):e7826. PubMed ID: 32119651
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis.
    Flex E; Jaiswal M; Pantaleoni F; Martinelli S; Strullu M; Fansa EK; Caye A; De Luca A; Lepri F; Dvorsky R; Pannone L; Paolacci S; Zhang SC; Fodale V; Bocchinfuso G; Rossi C; Burkitt-Wright EM; Farrotti A; Stellacci E; Cecchetti S; Ferese R; Bottero L; Castro S; Fenneteau O; Brethon B; Sanchez M; Roberts AE; Yntema HG; Van Der Burgt I; Cianci P; Bondeson ML; Cristina Digilio M; Zampino G; Kerr B; Aoki Y; Loh ML; Palleschi A; Di Schiavi E; Carè A; Selicorni A; Dallapiccola B; Cirstea IC; Stella L; Zenker M; Gelb BD; Cavé H; Ahmadian MR; Tartaglia M
    Hum Mol Genet; 2014 Aug; 23(16):4315-27. PubMed ID: 24705357
    [TBL] [Abstract][Full Text] [Related]  

  • 86. KRAS gene mutations in Noonan syndrome familial cases cluster in the vicinity of the switch II region of the G-domain: report of another family with metopic craniosynostosis.
    Brasil AS; Malaquias AC; Kim CA; Krieger JE; Jorge AA; Pereira AC; Bertola DR
    Am J Med Genet A; 2012 May; 158A(5):1178-84. PubMed ID: 22488932
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.
    Leung GKC; Luk HM; Tang VHM; Gao WW; Mak CCY; Yu MHC; Wong WL; Chu YWY; Yang WL; Wong WHS; Ma ACH; Leung AYH; Jin DY; Chan KYK; Allanson J; Lo IFM; Chung BHY
    Sci Rep; 2018 Feb; 8(1):2421. PubMed ID: 29402968
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Antenatal diagnosis of cardio-facio-cutaneous syndrome: Prenatal characteristics and contribution of fetal facial dysmorphic signs in utero. About a case and review of literature.
    Biard JM; Steenhaut P; Bernard P; Race V; Sznajer Y
    Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():232-241. PubMed ID: 31336229
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1-PPP1CB complexes.
    Umeki I; Niihori T; Abe T; Kanno SI; Okamoto N; Mizuno S; Kurosawa K; Nagasaki K; Yoshida M; Ohashi H; Inoue SI; Matsubara Y; Fujiwara I; Kure S; Aoki Y
    Hum Genet; 2019 Jan; 138(1):21-35. PubMed ID: 30368668
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Cardiofaciocutaneous syndrome, a Noonan syndrome related disorder: clinical and molecular findings in 11 patients].
    Carcavilla A; García-Miñaúr S; Pérez-Aytés A; Vendrell T; Pinto I; Guillén-Navarro E; González-Meneses A; Aoki Y; Grinberg D; Ezquieta B
    Med Clin (Barc); 2015 Jan; 144(2):67-72. PubMed ID: 25194980
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Effects of Noonan Syndrome-Germline Mutations on Mitochondria and Energy Metabolism.
    Bajia D; Bottani E; Derwich K
    Cells; 2022 Oct; 11(19):. PubMed ID: 36231062
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Contribution of RIT1 mutations to the pathogenesis of Noonan syndrome: four new cases and further evidence of heterogeneity.
    Gos M; Fahiminiya S; Poznański J; Klapecki J; Obersztyn E; Piotrowicz M; Wierzba J; Posmyk R; Bal J; Majewski J
    Am J Med Genet A; 2014 Sep; 164A(9):2310-6. PubMed ID: 24939608
    [No Abstract]   [Full Text] [Related]  

  • 93. Copy number variants and rasopathies: germline KRAS duplication in a patient with syndrome including pigmentation abnormalities.
    Gilbert-Dussardier B; Briand-Suleau A; Laurendeau I; Bilan F; Cavé H; Verloes A; Vidaud M; Vidaud D; Pasmant E
    Orphanet J Rare Dis; 2016 Jul; 11(1):101. PubMed ID: 27450488
    [TBL] [Abstract][Full Text] [Related]  

  • 94. A restricted spectrum of NRAS mutations causes Noonan syndrome.
    Cirstea IC; Kutsche K; Dvorsky R; Gremer L; Carta C; Horn D; Roberts AE; Lepri F; Merbitz-Zahradnik T; König R; Kratz CP; Pantaleoni F; Dentici ML; Joshi VA; Kucherlapati RS; Mazzanti L; Mundlos S; Patton MA; Silengo MC; Rossi C; Zampino G; Digilio C; Stuppia L; Seemanova E; Pennacchio LA; Gelb BD; Dallapiccola B; Wittinghofer A; Ahmadian MR; Tartaglia M; Zenker M
    Nat Genet; 2010 Jan; 42(1):27-9. PubMed ID: 19966803
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Mutations in RIT1 cause Noonan syndrome - additional functional evidence and expanding the clinical phenotype.
    Koenighofer M; Hung CY; McCauley JL; Dallman J; Back EJ; Mihalek I; Gripp KW; Sol-Church K; Rusconi P; Zhang Z; Shi GX; Andres DA; Bodamer OA
    Clin Genet; 2016 Mar; 89(3):359-66. PubMed ID: 25959749
    [TBL] [Abstract][Full Text] [Related]  

  • 96. RASopathies: The musculoskeletal consequences and their etiology and pathogenesis.
    Fowlkes JL; Thrailkill KM; Bunn RC
    Bone; 2021 Nov; 152():116060. PubMed ID: 34144233
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Germline-Activating RRAS2 Mutations Cause Noonan Syndrome.
    Niihori T; Nagai K; Fujita A; Ohashi H; Okamoto N; Okada S; Harada A; Kihara H; Arbogast T; Funayama R; Shirota M; Nakayama K; Abe T; Inoue SI; Tsai IC; Matsumoto N; Davis EE; Katsanis N; Aoki Y
    Am J Hum Genet; 2019 Jun; 104(6):1233-1240. PubMed ID: 31130285
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Cancer incidence and surveillance strategies in individuals with RASopathies.
    Ney G; Gross A; Livinski A; Kratz CP; Stewart DR
    Am J Med Genet C Semin Med Genet; 2022 Dec; 190(4):530-540. PubMed ID: 36533693
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Complicated ventricular arrhythmia and hematologic myeloproliferative disorder in RIT1-associated Noonan syndrome: Expanding the phenotype and review of the literature.
    Aly SA; Boyer KM; Muller BA; Marini D; Jones CH; Nguyen HH
    Mol Genet Genomic Med; 2020 Jul; 8(7):e1253. PubMed ID: 32396283
    [TBL] [Abstract][Full Text] [Related]  

  • 100. PHENOTYPIC CONSEQUENCES AND THE MALIGNANCY RISK IN FAMILIAL NOONAN SYNDROME DUE TO A RARE P.S427G RAF1 MUTATION.
    Pelc M; Ciara E; Jezela-Stanek A; Krajewska-Walasek M
    Genet Couns; 2016; 27(3):325-333. PubMed ID: 30204961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.